{"log_id": 3535728407219906258, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 9e-06, "average": 0.998408, "min": 0.985022}, "location": {"width": 825, "top": 260, "height": 38, "left": 239}, "words": "按临床剂量给药时,单次给药后终末半衰期为14.2小时,随剂量增加而增加。重"}, {"probability": {"variance": 5.7e-05, "average": 0.996302, "min": 0.962401}, "location": {"width": 859, "top": 307, "height": 38, "left": 199}, "words": "复给药有效半衰期为24小时,提示有一定蓄积。本品主要通过CYP3A4/5酶代谢后由"}, {"probability": {"variance": 0.000335, "average": 0.995475, "min": 0.884072}, "location": {"width": 866, "top": 354, "height": 37, "left": 198}, "words": "粪便排泄。仅有不到2%(本品和代谢产物)由尿排出。从粪便中回收的原形拉帕替尼占"}, {"probability": {"variance": 0.001909, "average": 0.98837, "min": 0.789057}, "location": {"width": 446, "top": 404, "height": 32, "left": 200}, "words": "口服剂量比例的中位数为27%(范围3-67%"}, {"probability": {"variance": 0.000155, "average": 0.994622, "min": 0.956258}, "location": {"width": 263, "top": 477, "height": 31, "left": 199}, "words": "年龄、性别或种族的影响"}, {"probability": {"variance": 0, "average": 0.999591, "min": 0.998662}, "location": {"width": 607, "top": 531, "height": 36, "left": 201}, "words": "未开展年龄、性别或种族对拉帕替尼药代动力学影响的研究"}, {"probability": {"variance": 3e-06, "average": 0.998766, "min": 0.995912}, "location": {"width": 86, "top": 596, "height": 28, "left": 203}, "words": "QT延长"}, {"probability": {"variance": 0.053695, "average": 0.668718, "min": 0.481061}, "location": {"width": 110, "top": 601, "height": 45, "left": 859}, "words": "份有公"}, {"probability": {"variance": 3e-06, "average": 0.998857, "min": 0.991023}, "location": {"width": 880, "top": 645, "height": 38, "left": 200}, "words": "作为非对照、开放性剂量递增研究的一部分,在晚期癌症患者中对拉帕替尼导致QT延"}, {"probability": {"variance": 0.00188, "average": 0.990362, "min": 0.728737}, "location": {"width": 805, "top": 678, "height": 33, "left": 200}, "words": "长的可能性进行了评价。81例患者接受拉帕替尼,每日剂量范围为175mg/天至"}, {"probability": {"variance": 0.004242, "average": 0.986621, "min": 0.575704}, "location": {"width": 851, "top": 705, "height": 39, "left": 215}, "words": "800mg/天。于第1天至第14天进行连续的ECG检查,评价拉帕替尼对QT间期的作"}, {"probability": {"variance": 0.013409, "average": 0.975994, "min": 0.385662}, "location": {"width": 639, "top": 732, "height": 42, "left": 200}, "words": "用。数据分析提示QTc间期始终随药物浓度的升高而延长"}, {"probability": {"variance": 1.2e-05, "average": 0.997641, "min": 0.99032}, "location": {"width": 144, "top": 847, "height": 27, "left": 202}, "words": "特殊患者人群"}, {"probability": {"variance": 1e-06, "average": 0.99914, "min": 0.997364}, "location": {"width": 121, "top": 910, "height": 28, "left": 203}, "words": "肾脏损害者"}, {"probability": {"variance": 1e-06, "average": 0.999272, "min": 0.997052}, "location": {"width": 815, "top": 968, "height": 35, "left": 244}, "words": "没有对本品在肾脏损害的患者或进行血液透析的患者的药代动力学进行特定的研"}, {"probability": {"variance": 2e-06, "average": 0.999329, "min": 0.992623}, "location": {"width": 880, "top": 1015, "height": 32, "left": 203}, "words": "究。但是,肾脏损害可能不影响本品的药代动力学,因为仅有不到2%的药物(本品原"}, {"probability": {"variance": 0, "average": 0.999327, "min": 0.997881}, "location": {"width": 354, "top": 1064, "height": 28, "left": 203}, "words": "型药和代谢产物)是由肾脏清除的"}, {"probability": {"variance": 0, "average": 0.999478, "min": 0.99888}, "location": {"width": 99, "top": 1192, "height": 28, "left": 203}, "words": "肝脏损害"}, {"probability": {"variance": 1.5e-05, "average": 0.987991, "min": 0.984113}, "location": {"width": 169, "top": 1176, "height": 57, "left": 824}, "words": " GUANGDONG PHARMA"}, {"probability": {"variance": 0.000129, "average": 0.993389, "min": 0.973694}, "location": {"width": 176, "top": 1194, "height": 69, "left": 791}, "words": "华润广东"}, {"probability": {"variance": 0.030549, "average": 0.91637, "min": 0.368456}, "location": {"width": 827, "top": 1245, "height": 45, "left": 251}, "words": "在中度(8例)肝损害和重度4例)肝损害的患者和到药)本品"}, {"probability": {"variance": 1e-06, "average": 0.999503, "min": 0.997437}, "location": {"width": 190, "top": 1299, "height": 28, "left": 205}, "words": "的药代动力学研究"}, {"probability": {"variance": 0, "average": 0.716643, "min": 0.716643}, "location": {"width": 22, "top": 1292, "height": 22, "left": 829}, "words": "H"}, {"probability": {"variance": 0.033849, "average": 0.795582, "min": 0.5369}, "location": {"width": 83, "top": 1303, "height": 29, "left": 879}, "words": "米01"}, {"probability": {"variance": 0.000304, "average": 0.993883, "min": 0.911378}, "location": {"width": 824, "top": 1358, "height": 35, "left": 251}, "words": "给予单药本品口服100mg,中度和重度肝损害患者的本品全身暴露量(AUC)分别"}, {"probability": {"variance": 4e-05, "average": 0.996741, "min": 0.975714}, "location": {"width": 882, "top": 1405, "height": 34, "left": 206}, "words": "增加56%和85%。因此,由于药物暴露量的增加,有肝损害的患者服用本品应谨慎。患"}], "language": 3}